CAR-T specialist Caribou culls pipeline and seeks exit deal

Caribou Biosciences is discontinuing its two allogeneic CAR-T programmes, vispa-cel for relapsed or refractory B cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma, and will make substantial workforce cuts, having had 97 full-time employees as of February 2026. CEO Rachel Haurwitz said the financing environment for allogeneic CAR-T made raising capital impossible, as investors shift toward in vivo approaches. The board is now seeking exit routes, including a merger, acquisition, business combination or asset sale.